{"id":"sr121463b","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the 5-HT6 receptor, SR121463B is expected to increase the levels of acetylcholine in the brain, which may help to improve cognitive function in patients with Alzheimer's disease. This mechanism of action is thought to be beneficial in the treatment of cognitive impairment associated with neurodegenerative diseases.","oneSentence":"SR121463B is a small molecule that acts as a selective and potent inhibitor of the serotonin 5-HT6 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:58.532Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT00358878","phase":"PHASE3","title":"Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-07","conditions":"Ascites, Liver Cirrhosis","enrollment":463},{"nctId":"NCT00728091","phase":"PHASE3","title":"A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2008-07","conditions":"Hyponatremia, Inappropriate ADH Syndrome","enrollment":2},{"nctId":"NCT00359437","phase":"PHASE3","title":"Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver","status":"TERMINATED","sponsor":"Sanofi","startDate":"2006-07","conditions":"Ascites, Liver Cirrhosis","enrollment":501},{"nctId":"NCT00366795","phase":"PHASE3","title":"Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver","status":"TERMINATED","sponsor":"Sanofi","startDate":"2006-08","conditions":"Ascites, Liver Cirrhosis","enrollment":241},{"nctId":"NCT00264914","phase":"PHASE3","title":"Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-07","conditions":"Inappropriate ADH Syndrome, Hyponatremia","enrollment":57},{"nctId":"NCT00501384","phase":"PHASE2","title":"Satavaptan Dose-Ranging Study in the Prevention of Ascites","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-04","conditions":"Ascites, Liver Cirrhosis","enrollment":151},{"nctId":"NCT00501722","phase":"PHASE2","title":"Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-04","conditions":"Ascites, Liver Cirrhosis","enrollment":110},{"nctId":"NCT00264927","phase":"PHASE3","title":"Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-05","conditions":"Inappropriate ADH Syndrome, Hyponatremia","enrollment":77},{"nctId":"NCT00274326","phase":"PHASE3","title":"DILIPO (DILutIonal HyPOnatremia)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-05","conditions":"Congestive Heart Failure","enrollment":150},{"nctId":"NCT00032734","phase":"PHASE2","title":"Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-06","conditions":"Syndrome of Inappropriate ADH (SIADH) Secretion, Hyponatremia","enrollment":35},{"nctId":"NCT00501566","phase":"PHASE2","title":"Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-04","conditions":"Ascites, Liver Cirrhosis","enrollment":148}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SR121463B","genericName":"SR121463B","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SR121463B is a small molecule that acts as a selective and potent inhibitor of the serotonin 5-HT6 receptor. Used for Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}